Why the study?
The study aimed to compare the efficacy of ARNI therapy with ARB therapy for cardiovascular outcomes in real-world patients with heart failure with reduced ejection fraction.
Does sacubitril/valsartan reduce the composite of cardiovascular death and hospitalization for worsening heart failure compared to ARB therapy in patients with HFrEF?
Population
Patients with heart failure with reduced ejection fraction from the Chang Gung Research Database
Comparison
ARNI therapy vs ARB therapy
Design
Retrospective propensity score-matched cohort study
Key result
Sacubitril/valsartan was superior to ARB therapy in reducing the composite of cardiovascular death and hospitalization for worsening HF (HR 0.74; 95% CI 0.57-0.96).
Authors
Loading...
ARNI was associated with lower CV risk than ARB in HFrEF; extends observational support but leaves randomized confirmation open.
Cohort
Does sacubitril/valsartan reduce the composite of cardiovascular death and hospitalization for worsening heart failure compared to ARB therapy in patients with HFrEF?
Hazard Ratio: 0.74 (95% CI 0.57–0.96)
In a real-world Taiwanese cohort of HFrEF patients, sacubitril/valsartan significantly reduced the composite of cardiovascular death and heart failure hospitalization compared to ARB therapy, despite the use of lower-than-trial doses.
Chang et al. (2020) conducted a cohort in Heart failure with reduced ejection fraction. Sacubitril/valsartan vs. Angiotensin receptor blocker (ARB) therapy was evaluated on Composite of cardiovascular death and hospitalization for worsening HF (HR 0.74, 95% CI 0.57-0.96). Sacubitril/valsartan was superior to ARB therapy in reducing the composite of cardiovascular death and hospitalization for worsening HF (HR 0.74; 95% CI 0.57-0.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: